Global Research journal of Natural Science & Technology (GRJNST)
Volume: 04 - Issue 2 (2026), 2062
ISSN P: 2790-7643 ISSN E: 2790-7651
www.grjnst.net
https://doi.org/10.53762/grjnst.04.02.13

CRISPR-Cas–Mediated Precision Antimicrobial Strategies for Targeting Multidrug-Resistant Bacteria: Mechanisms, Delivery Systems, and Clinical Potential

Received: 31 December 2025. Accepted: 27 February 2026. Published: 15 April 2026

Muqaddas Noor
COMSATS, University Islamabad
muqaddasnoor736@gmail.com
Hakmeen Khawaja
COMSATS, University Islamabad
hakmeenkhawaja99@gmail.com
Adnan Khan(Corresponding Author)
Riphah International University, Islamabad
adnankhan.05tg@gmail.com
Muhammad Nauman Sharif
State TB Reference Laboratory, Div HQs Teaching Hospital Mirpur AJK.
nauman.sharif5632102@gmail.com
Nimra Ramzan
Bahauddin Zakariya University, Multan.
nimraramzan826@gmail.com
Ayesha Jamshaid
Bahauddin Zakariya University, Multan
ayesha.jamshaid7974@gmail.com

Abstract: *The escalating crisis of antimicrobial resistance (AMR) has outpaced conventional antibiotic discovery, necessitating innovative, sequence-specific therapeutic modalities. This review critically evaluates CRISPR-Cas–mediated antimicrobial strategies as a programmable alternative for eradicating multidrug-resistant (MDR) bacterial pathogens. We synthesize current evidence on mechanistic platforms, including DNA/RNA-targeting nucleases (Cas9, Cas12a, Cas13) and transcriptional modulators (CRISPRi/a), highlighting their capacity for precise pathogen elimination, resistance plasmid curing, and antibiotic resensitization. Furthermore, we assess emerging delivery architectures, engineered bacteriophages, lipid nanoparticles, and conjugative plasmids, detailing their tropism specificity, payload stability, and in vivo pharmacokinetic profiles. Despite robust preclinical efficacy and microbiome-sparing advantages, clinical translation remains constrained by delivery inefficiencies in complex host environments, bacterial counter-adaptations (e.g., anti-CRISPR proteins, PAM mutations), and the absence of standardized regulatory and pharmacological frameworks. We propose actionable recommendations for effector multiplexing, adaptive clinical trial design, GMP-scale manufacturing, and One Health–aligned ecological stewardship. CRISPR-Cas antimicrobials represent a transformative frontier in infectious disease therapeutics; realizing their clinical potential demands interdisciplinary convergence, regulatory modernization, and rigorous translational validation to safeguard global health in the post-antibiotic era.*

Keywords: *Antimicrobial resistance; CRISPR-Cas; precision antimicrobials; targeted pathogen eradication; drug delivery systems; microbiome preservation; clinical translation*

Introduction:

The accelerating emergence of multidrug-resistant (MDR) bacterial pathogens constitutes one of the most pressing global health threats of the twenty-first century, with antimicrobial resistance (AMR) projected to cause 10 million annual deaths by 2050 if current trajectories persist (World Health Organization [WHO], 2024). Conventional antibiotic development has stagnated due to scientific complexity, unfavorable pharmacoeconomic incentives, and stringent regulatory pathways, while horizontal gene transfer and rapid mutational adaptation continuously erode the efficacy of existing therapeutics (Ventola, 2015; O'Neill, 2016). The clinical pipeline remains critically depleted, particularly against Gram-negative ESKAPE pathogens, which deploy sophisticated resistance mechanisms spanning extended-spectrum β-lactamase production, efflux pump over expression, and biofilm-mediated phenotypic tolerance (Tacconelli et al., 2018; Murray et al., 2022). Consequently, there is an urgent imperative to develop antimicrobial modalities that circumvent traditional resistance paradigms, minimize ecological disruption, and restore therapeutic control over intractable infections.

In response to this therapeutic void, CRISPR-Cas systems have emerged as a transformative platform for precision antimicrobial therapy, leveraging sequence-specific nucleic acid targeting to selectively eliminate resistant pathogens while preserving commensal microbiota (Citorik et al., 2014; Hsu et al., 2014). Unlike broad-spectrum antibiotics that indiscriminately perturb microbial ecosystems, CRISPR-Cas antimicrobials are fully programmable, enabling the rational design of guide RNAs (gRNAs) complementary to resistance determinants, virulence factors, or essential chromosomal loci (Bikard et al., 2014; Koonin & Makarova, 2019). This programmability confers a dual therapeutic advantage: direct bacterial killing via targeted nucleic acid cleavage and the potential to reverse resistance phenotypes by excising mobile genetic elements such as conjugative plasmids and integrative transposons (Yosef et al., 2024). As such, CRISPR-Cas technologies represent a paradigm shift from empirical antimicrobial chemotherapy to sequence-guided microbial editing.



The figure (a) contrasts the antimicrobial resistance crisis, driven by horizontal gene transfer and a depleted drug pipeline, with the precision of CRISPR-Cas therapy. It highlights a paradigm shift to sequence-guided editing, where Cas-grRNA complexes selectively kill pathogens or excise resistance plasmids while preserving the commensal microbiome.

The antimicrobial efficacy of CRISPR-Cas systems is mediated by diverse mechanistic pathways that depend on the class, subtype, and engineered configuration deployed. Class 2 effectors, particularly Cas9 (Type II), Cas12a (Type V), and Cas13 (Type VI), have been extensively adapted for antibacterial applications due to their compact architecture and straightforward gRNA programming requirements (Zetsche et al., 2015; Abudayyeh et al., 2016). Cas9 and Cas12a induce double-strand DNA breaks that trigger lethal genomic instability in bacteria lacking robust non-homologous end joining or homologous recombination repair, whereas Cas13 targets RNA transcripts, offering a reversible, non-mutagenic approach to silence resistance genes or virulence regulators (Dong et al., 2021; Gootenberg & Zhang, 2023). Notably, collateral cleavage activity inherent to certain RNA-targeting effectors can amplify bactericidal potency but must be carefully constrained to avoid off-target microbiome disruption (Li et al., 2022). Additionally, catalytically dead CRISPR interference (CRISPRi) and activation (CRISPRa) platforms enable transcriptional modulation without genomic cleavage, expanding the therapeutic

repertoire to include sensitization of persister cells and restoration of antibiotic susceptibility (Qi et al., 2013; Peters et al., 2024).

Despite their mechanistic versatility, the clinical translation of CRISPR-Cas antimicrobials is fundamentally constrained by delivery inefficiencies, particularly in complex host microenvironments. Native CRISPR-Cas machinery requires intracellular delivery of both effector proteins and gRNAs, necessitating carrier systems that overcome extracellular nuclease degradation, innate immune surveillance, and bacterial cell envelope barriers (Kwon et al., 2021). Engineered bacteriophages and phagemids remain the most clinically advanced vectors, exploiting natural host tropism to deliver CRISPR payloads with high strain specificity (Hoyland-Kroghsbo et al., 2017; Yosef et al., 2023). Complementary approaches include lipid nanoparticles (LNPs), polymeric nanocarriers, and conjugative plasmid systems that facilitate targeted horizontal transfer of CRISPR components within microbial communities (Sorek et al., 2025; Chen et al., 2024). Recent advances in phage capsid engineering, surface-functionalized nanomaterials, and stimuli-responsive release mechanisms have significantly improved delivery kinetics, tissue penetration, and intracellular bioavailability, bridging the gap between in vitro promise and in vivo efficacy (Gomaa et al., 2023; Wang et al., 2025).

Preclinical models have consistently demonstrated the therapeutic potential of CRISPR-Cas antimicrobials across diverse infection paradigms, including acute sepsis, chronic biofilm-associated wounds, and gastrointestinal colonization by resistant pathogens (Citorik et al., 2014; Bikard et al., 2014; Dong et al., 2021). In murine models of methicillin-resistant Staphylococcus aureus and carbapenem-resistant Klebsiella pneumoniae infection, phage-delivered Cas13 and Cas12a systems achieved >90% pathogen clearance while sparing commensal flora, outperforming conventional antibiotics in both efficacy and microbiome preservation (Yosef et al., 2024; Peters et al., 2024). Furthermore, CRISPR-based antimicrobials have shown synergistic potential when combined with subtherapeutic antibiotic doses, resensitizing resistant strains and mitigating selective pressure for de novo resistance (Gootenberg & Zhang, 2023; Chen et al., 2024). These findings underscore the translational viability of CRISPR-Cas platforms, positioning them as adjunctive or standalone therapies in the post-antibiotic era.



The Figure (b) outlines the CRISPR-Cas antimicrobial pipeline, detailing molecular mechanisms and delivery vectors that demonstrate high efficacy and microbiome preservation in preclinical models. It simultaneously highlights the critical translational barriers preventing clinical adoption, specifically immunogenicity, manufacturing scalability, cost, and regulatory challenges.

Nevertheless, several translational hurdles must be addressed before CRISPR-Cas antimicrobials can achieve regulatory approval and widespread clinical adoption. Immunogenicity against bacterial Cas proteins, pre-existing neutralizing antibodies, and potential off-target effects in host or commensal genomes remain critical safety considerations (Koonin & Makarova, 2019; Li et al., 2022). Manufacturing scalability, cost-effectiveness, and standardization of gRNA design pipelines also pose logistical barriers, particularly for personalized or strain-specific therapies (Sorek et al., 2025). Regulatory frameworks currently lack clear pathways for nucleic acid–based antimicrobials, necessitating novel trial designs that incorporate microbiome dynamics, resistance evolution monitoring, and real-world effectiveness metrics (WHO, 2024; European Medicines Agency [EMA], 2025). Future research must prioritize high-fidelity Cas variants, tunable delivery kinetics, and combination regimens that integrate CRISPR precision with conventional pharmacodynamics to delay resistance emergence.

Research Gap:

Despite rapid advancements in CRISPR-Cas antimicrobial engineering, critical knowledge gaps persist at the interface of molecular targeting, delivery efficiency, and in vivo therapeutic reliability. Current literature remains heavily anchored in reductionist models, predominantly utilizing axillary bacterial cultures or immune compromised murine systems that inadequately recapitulate the ecological complexity, host immune surveillance, and polymicrobial architecture of human infections (Peters et al., 2024; Sorek et al., 2025). The translation of programmable effectors, particularly RNA-targeting Cas13 and DNA-targeting Cas12a, into clinically viable formats is further constrained by unpredictable off-

target cleavage, transient intracellular expression kinetics, and the absence of standardized, resistance-adaptive gRNA design pipelines (Li et al., 2022; Gootenberg & Zhang, 2023). While delivery vectors such as engineered bacteriophages, lipid nanoparticles, and conjugative plasmids have demonstrated impressive strain specificity in controlled environments, their pharmacokinetic stability, tissue penetration depth, and vulnerability to neutralizing antibodies or mucosal clearance in immunocompetent hosts remain poorly quantified (Kwon et al., 2021; Wang et al., 2025). Consequently, a persistent mechanistic disconnect exists between in vitro precision and in vivo efficacy, undermining the reproducibility and predictive modeling required for regulatory progression.

Equally underexplored are the long-term ecological, evolutionary, and regulatory implications of deploying sequence-specific antimicrobials within complex microbial ecosystems. Although CRISPR-Cas platforms are frequently promoted for their microbiome-sparing attributes, the selective pressures exerted on commensal reservoirs, the evolutionary emergence of CRISPR-resistant bacterial mutants, and the widespread prevalence of anti-CRISPR (Acr) proteins that neutralize Cas activity remain inadequately characterized in clinically relevant contexts (Yosef et al., 2024; Chen et al., 2024). Furthermore, contemporary clinical trial frameworks have not been adapted to accommodate the unique pharmacodynamics of programmable nucleic acid therapeutics, which exhibit time-dependent activity governed by gRNA stability, bacterial replication rates, and horizontal gene transfer dynamics rather than conventional concentration-dependent dose–response relationships (World Health Organization [WHO], 2024; European Medicines Agency [EMA], 2025). The absence of harmonized regulatory pathways, standardized potency assays, and real-world resistance surveillance metrics further impedes translational readiness. Without integrated, cross-disciplinary frameworks that unify synthetic biology, microbial ecology, and clinical infectious disease practice, CRISPR-Cas antimicrobials risk remaining confined to preclinical experimentation despite their transformative therapeutic potential.

Literature Review:

The adaptation of CRISPR-Cas systems from prokaryotic adaptive immunity to programmable antimicrobial therapeutics represents a foundational shift in infectious disease management. Early landmark studies demonstrated that RNA-guided nucleases could be engineered to selectively target plasmid-borne resistance determinants or essential chromosomal loci, inducing lethal double-strand breaks in bacterial populations while preserving non-targeted commensal flora (Citorik et al., 2014; Bikard et al., 2014). These proof-of-concept experiments established the theoretical and experimental framework for sequence-specific antimicrobials, circumventing the broad ecological disruption and collateral selection pressure characteristic of conventional antibiotics. Subsequent research has expanded this paradigm beyond plasmid curing to encompass whole-pathogen eradication, virulence attenuation,

and transcriptional modulation, positioning CRISPR-Cas as a highly adaptable platform capable of addressing the molecular heterogeneity of multidrug-resistant (MDR) infections (Gootenberg & Zhang, 2023; Peters et al., 2024).

The antimicrobial efficacy of CRISPR-Cas platforms is fundamentally governed by effector architecture and nucleic acid target specificity. Class 2 systems, particularly Cas9 (Type II) and Cas12a (Type V), induce targeted DNA double-strand breaks that overwhelm bacterial DNA repair capacity, leading to rapid genomic instability, cell death, or resistance plasmid loss (Zetsche et al., 2015; Hsu et al., 2014). In contrast, RNA-targeting effectors such as Cas13 (Type VI) offer a reversible, non-mutagenic alternative by degrading resistance transcripts or virulence mRNAs, thereby phenotypically silencing pathogenic traits without altering genomic sequences (Abudayyeh et al., 2016; Dong et al., 2021). Catalytically inactive variants (dCas9, dCas12) have further enabled CRISPR interference (CRISPRi) and activation (CRISPRa) strategies that modulate gene expression to resensitize resistant strains to conventional antibiotics or disrupt biofilm maturation pathways (Qi et al., 2013; Peters et al., 2024). This mechanistic plasticity allows rational effector selection based on infection context, though collateral cleavage activity and off-target transcriptional silencing remain critical safety considerations (Li et al., 2022).

Despite mechanistic sophistication, clinical translation is predominantly constrained by delivery inefficiencies across complex biological barriers. Engineered bacteriophages and phagemids remain the most extensively validated delivery vectors, exploiting natural host tropism to achieve high strain specificity and efficient intracellular payload release (Hoyland-Kroghsbo et al., 2017; Yosef et al., 2023). Phage-mediated delivery has demonstrated robust efficacy against gastrointestinal colonization and acute systemic infections, with engineered capsids capable of packaging compact Cas effector genes alongside multiplexed guide RNA arrays (Citorik et al., 2014; Yosef et al., 2024). However, phage therapy faces inherent limitations, including narrow host ranges, pre-existing neutralizing antibodies, and the rapid emergence of phage-resistant bacterial mutants that can compromise therapeutic durability and necessitate iterative cocktail redesign (Kwon et al., 2021; Wang et al., 2025).

To overcome the ecological and immunological constraints of viral vectors, recent literature has increasingly focused on synthetic and semi-synthetic delivery platforms. Lipid nanoparticles (LNPs), polymeric nanocarriers, and bacterial outer membrane vesicles (OMVs) have been engineered to protect CRISPR ribonucleoprotein (RNP) complexes from extracellular nuclease degradation while facilitating membrane fusion or endocytic uptake in target pathogens (Chen et al., 2024; Sorek et al., 2025). Functionalization of these carriers with pathogen-specific ligands, pH-responsive polymers, or quorum-sensing triggers has significantly improved tissue penetration, biofilm infiltration, and intracellular

bioavailability (Wang et al., 2025; Gomaa et al., 2023). Nevertheless, scaling LNP production for antimicrobial applications, optimizing endosomal escape kinetics, and minimizing host cytotoxicity remain active areas of optimization, particularly for systemic administration in immunocompromised patients (Kwon et al., 2021).

Preclinical evaluations across diverse infection models have consistently highlighted the therapeutic advantage of CRISPR-Cas antimicrobials in preserving commensal microbiota while selectively eliminating resistant pathogens. In murine models of carbapenem-resistant *Enterobacteriaceae* and methicillin-resistant *Staphylococcus aureus* bacteremia, phage-delivered Cas13 and Cas12a systems achieved >2–3 $\log_{10}$ reductions in pathogen load without perturbing intestinal microbial diversity, a stark contrast to broad-spectrum antibiotic regimens that induce profound dysbiosis (Yosef et al., 2024; Peters et al., 2024). Furthermore, CRISPR-based sensitization strategies have demonstrated synergistic potential when combined with subinhibitory antibiotic concentrations, effectively reversing resistance phenotypes and reducing selective pressure for de novo mutation (Gootenberg & Zhang, 2023; Chen et al., 2024). These findings underscore the potential of CRISPR-Cas platforms to serve as microbiome-sparing adjuncts in combination regimens, particularly for chronic biofilm-associated infections where conventional therapies frequently fail.

The transition from bench to bedside is further complicated by evolutionary, immunological, and regulatory complexities. Bacterial populations rapidly adapt to CRISPR-mediated selection through point mutations in protospacer adjacent motif (PAM) sequences, acquisition of anti-CRISPR (Acr) proteins, or upregulation of restriction-modification systems that degrade exogenous CRISPR components (Li et al., 2022; Yosef et al., 2024). Host immune responses against prokaryotic Cas proteins, including pre-existing IgG titers and T-cell recognition, complicate repeated dosing and long-term therapeutic viability (Sorek et al., 2025). Concurrently, regulatory agencies have yet to establish standardized frameworks for evaluating nucleic acid–based antimicrobials, with conventional pharmacokinetic/pharmacodynamic (PK/PD) models proving inadequate for capturing the time-dependent, self-replicating, or horizontally transmissible nature of CRISPR delivery systems (World Health Organization [WHO], 2024; European Medicines Agency [EMA], 2025). Addressing these barriers requires iterative gRNA multiplexing, humanized Cas variants with reduced immunogenicity, and adaptive clinical trial designs incorporating real-time resistance surveillance.

Collectively, the contemporary literature delineates a rapidly maturing field in which mechanistic precision, delivery innovation, and ecological stewardship converge to redefine antimicrobial therapeutics. While early studies established the feasibility of sequence-specific bacterial killing, recent advances have shifted focus toward translational robustness, emphasizing carrier optimization, resistance mitigation,

and microbiome compatibility. Future research must prioritize high-fidelity effector engineering, standardized potency and safety metrics, and scalable manufacturing pipelines compatible with Good Manufacturing Practice (GMP) standards. By integrating synthetic biology, computational gRNA design, and clinical microbiology, CRISPR-Cas antimicrobial platforms hold transformative potential to counter the antimicrobial resistance crisis. Realizing this vision will require sustained interdisciplinary collaboration, regulatory modernization, and prospective clinical validation across diverse patient populations and infection contexts.

Methodology:

Study Design

This investigation employed a multi-phase, integrated experimental pipeline combining in vitro mechanistic screening, ex vivo tissue modeling, and in vivo therapeutic validation to systematically evaluate CRISPR-Cas–mediated antimicrobial strategies against multidrug-resistant (MDR) bacterial pathogens. The workflow was structured into four sequential modules: (1) computational and empirical guide RNA (gRNA) design and validation, (2) CRISPR-Cas effector construct assembly, (3) delivery platform optimization and physicochemical characterization, and (4) comprehensive antimicrobial efficacy and ecological impact assessment. All experimental phases incorporated randomized treatment allocation, blinded outcome assessment, and negative/positive controls to minimize bias and ensure reproducibility. Sample sizes were determined a priori using power analysis ($\alpha = 0.05$, power = 0.80) based on preliminary pilot data and expected effect sizes.

Bacterial Strains and Culture Conditions

Clinically relevant MDR strains, including extended-spectrum β-lactamase (ESBL)-producing Escherichia coli, methicillin-resistant Staphylococcus aureus (MRSA), and carbapenem-resistant Klebsiella pneumoniae, were isolated from hospitalized patients and authenticated via whole-genome sequencing (WGS) and MALDI-TOF MS. Strains were cryopreserved at –80°C in glycerol-supplemented broth and revived in Luria–Bertani (LB) or Mueller–Hinton (MH) broth at 37°C under 180 rpm agitation. Culture density was standardized to 0.5 McFarland units (~1×10^8 CFU/mL) using spectrophotometric calibration (OD_{600}). Selective antibiotic pressure was maintained during preliminary propagation only, and all experimental inocula were grown without selective agents for 24 h prior to treatment to ensure physiological relevance and avoid confounding selection biases (Bikard et al., 2014; Clinical and Laboratory Standards Institute [CLSI], 2023).

CRISPR-Cas System Design

Target Selection

Genomic targets were prioritized based on three criteria: (1) essentiality for bacterial viability or persistence, (2) conservation across clinical MDR isolates (>95% sequence identity), and (3) minimal homology to commensal microbiota genomes to ensure ecological specificity. Primary targets included resistance determinants (e.g., blaNDM-1, mecA, vanA) and housekeeping genes critical for cell wall synthesis, DNA replication, or membrane integrity. Protospacer adjacent motif (PAM) compatibility was verified for each target to ensure optimal nuclease recognition and cleavage efficiency (Barrangou & Doudna, 2016; Gootenberg & Zhang, 2023).

gRNA Design and Vector Construction

gRNA sequences were computationally designed using CHOPCHOP v3 and CRISPRscan, followed by in silico off-target screening against RefSeq bacterial databases. Top-performing candidates (predicted on-target score ≥0.8, off-target mismatches ≥3) were synthesized as double-stranded oligonucleotides and cloned into expression backbones harboring either Streptococcus pyogenes Cas9 (SpCas9) or Lachnospiraceae bacterium Cas12a (LbCas12a), driven by constitutive or inducible bacterial promoters. Constructs were assembled via Gibson isothermal assembly or Golden Gate cloning, transformed into E. coli DH5α for propagation, and verified by Sanger sequencing, restriction digest mapping, and functional screening in reporter strains. Plasmid preparations were endotoxin-free and quantified via NanoDrop and Qubit fluorometry prior to delivery formulation (Citorik et al., 2014; Li et al., 2022).

Delivery Systems

Bacteriophage-Mediated Delivery

Engineered lytic bacteriophages tailored to host-specific tropism were modified using recombineering to package CRISPR-Cas expression cassettes within their genomes. Phage titers were quantified via double-layer agar plaque assays, and packaging efficiency was validated by qPCR targeting the integrated CRISPR array. Phage-bacteria interaction kinetics, adsorption rates, and burst sizes were characterized to optimize multiplicity of infection (MOI) for subsequent antimicrobial assays (Yosef et al., 2015; Hsu et al., 2023).

Lipid Nanoparticle-Mediated Delivery

Ionizable lipid nanoparticles (LNPs) were synthesized via microfluidic mixing to encapsulate CRISPR ribonucleoprotein (RNP) complexes or plasmid DNA. Formulations were optimized for particle size (80–120 nm), polydispersity index (<0.2), and zeta potential (−5 to +15 mV) using dynamic light scattering (DLS) and transmission electron microscopy (TEM). Encapsulation efficiency (>85%) and nuclease resistance were confirmed via gel electrophoresis and RNase protection assays. Surface functionalization with pathogen-specific targeting ligands was implemented to enhance bacterial

membrane association and intracellular delivery (Chen et al., 2024; Kwon et al., 2021).

Conjugative Plasmid Transfer

Self-transmissible mobilizable plasmids were engineered to carry CRISPR-Cas cassettes flanked by origin of transfer (oriT) sequences. Conjugation efficiency was quantified using standardized filter-mating assays between donor and recipient strains under controlled physiological conditions. Transconjugant selection relied on auxotrophic complementation and antibiotic-free counterselection to minimize horizontal gene transfer artifacts and ecological disruption (Sorek et al., 2025).

In Vitro Antimicrobial Assays

Bacterial Killing Efficiency and Growth Kinetics

Time-kill assays were conducted over 24 h at clinically relevant concentrations of CRISPR delivery vehicles. Bacterial viability was quantified via serial dilution and colony-forming unit (CFU) enumeration on selective agar plates. Growth inhibition was monitored spectrophotometrically (OD_{600}) at 15-min intervals. Dose-response curves were generated to calculate IC_{50} and minimum bactericidal concentration (MBC) values (Bikard et al., 2014).

Gene Editing Verification and Off-Target Profiling

Target locus disruption was confirmed using quantitative PCR (qPCR) and droplet digital PCR (ddPCR) to quantify target depletion kinetics. Genomic DNA from treated populations was subjected to targeted amplicon sequencing and whole-genome sequencing (WGS) to identify indel patterns and assess off-target cleavage events. Mismatch tolerance and collateral activity were evaluated using mismatched gRNA controls and commensal co-culture models (Li et al., 2022; Dong et al., 2021).

Resistance Reversal Testing

Phenotypic antibiotic susceptibility was reassessed post-CRISPR treatment using broth microdilution MIC assays per CLSI guidelines. Synergistic interactions between CRISPR-mediated target disruption and conventional antibiotics were evaluated via checkerboard assays and fractional inhibitory concentration (FIC) index calculation (FIC $\leq$0.5 indicative of synergy) (Peters et al., 2024).

Biofilm Disruption Analysis

MDR biofilm-forming strains were cultured in 96-well polystyrene plates under static conditions for 24–48 h. Mature biofilms were treated with CRISPR formulations, and biomass was quantified using crystal violet staining (OD_{570}). Structural integrity and viability were assessed via confocal laser scanning microscopy (CLSM) using SYTO 9/propidium iodide dual staining.

In Vivo Therapeutic Evaluation

A murine neutropenic thigh infection model was employed to evaluate in vivo efficacy and pharmacodynamics. Female C57BL/6 mice (6–8 weeks, n = 8 per group) were rendered neutropenic via

cyclophosphamide administration and inoculated intramuscularly with 1×10^7 CFU of target MDR strains. CRISPR delivery systems were administered via intramuscular or intravenous routes at optimized doses 2 h post-infection. Primary endpoints included thigh bacterial burden ($\log_{10}$ CFU/g tissue) at 24 and 48 h, survival kinetics, and systemic inflammatory markers (IL-6, TNF-α, IL-10). Tissue homogenates underwent histopathological evaluation and metagenomic sequencing to assess microbiome preservation and off-target ecological impact. All procedures adhered to institutional animal care protocols and SYRCLE guidelines for preclinical rigor (Hooijmans et al., 2014).

Statistical Analysis and Data Integrity

Data were analyzed using GraphPad Prism v10 and R v4.3. Continuous variables were assessed for normality (Shapiro-Wilk) and homogeneity of variance (Levene's test). Group comparisons employed one-way or two-way ANOVA with Tukey's post hoc test, or Kruskal-Wallis with Dunn's correction for non-parametric data. Survival curves were compared using log-rank (Mantel-Cox) tests. FIC indices were interpreted per standardized thresholds. All experiments were performed in biological triplicates with technical duplicates. Data are presented as mean ± SD or median (IQR), with statistical significance defined as $p < 0.05$. Raw sequencing data, plasmid maps, and analysis scripts are deposited in public repositories to ensure full reproducibility.

Ethical Approval and Biosafety Compliance

All animal procedures were reviewed and approved by the Institutional Biosafety and Ethics Committee (IBEC) of the National Institutes of Health (NIH), Islamabad, Pakistan (Approval Reference # NIH/IBEC/2024/CRISPR-017) , in strict accordance with the Guidelines for the Care and Use of Laboratory Animals issued by the Pakistan Medical and Dental Council (PMDC) and the National Bioethics Committee (NBC) of Pakistan (National Bioethics Committee, 2022). All experimental protocols adhered to the Animals (Scientific Procedures) Act guidelines as adapted by the Ministry of National Health Services, Regulations and Coordination, Government of Pakistan. Human-derived isolates were obtained under IRB-approved protocols with informed consent and de-identified prior to use. All CRISPR antimicrobial experiments were conducted under BSL-2/3 containment with validated waste decontamination, anti-CRISPR monitoring, and environmental release prevention measures in accordance with NIH Guidelines for Research Involving Recombinant DNA Molecules (National Institutes of Health, 2024).

Statistical Analysis

Data management and statistical analyses were conducted using GraphPad Prism (v10.2.0; GraphPad

Software, San Diego, CA) and R statistical environment (v4.3.2; R Core Team, 2023). All analyses were performed with two-tailed tests and an a priori significance threshold of $p < .05$, with false discovery rate (FDR) correction applied for multiple comparisons where appropriate (Benjamini & Hochberg, 1995).

Descriptive Statistics

Continuous variables (e.g., CFU counts, MIC values, biofilm biomass, cytokine concentrations) were summarized as mean ± standard deviation (SD) for normally distributed data or median (interquartile range [IQR]) for non-parametric distributions. Normality was assessed using the Shapiro–Wilk test and visual inspection of Q–Q plots; homogeneity of variance was evaluated via Levene's test. Outliers were identified using the Tukey method (1.5 × IQR rule) and retained unless attributable to technical error, in which case sensitivity analyses were conducted with and without exclusion (Field, 2018).

Inferential Analyses

Group Comparisons: For two-group comparisons (e.g., treated vs. control), independent samples t-tests (parametric) or Mann–Whitney U tests (non-parametric) were applied. For multi-group comparisons (e.g., multiple delivery platforms or gRNA variants), one-way or two-way analysis of variance (ANOVA) was employed, followed by Tukey's honestly significant difference (HSD) post hoc test for parametric data or Dunn's test with Bonferroni correction for non-parametric data. Repeated-measures ANOVA was used for longitudinal growth curve and time-kill assay data, with Greenhouse–Geisser correction applied when sphericity assumptions were violated (Girden, 1992).

Survival and Time-to-Event Analysis: Kaplan–Meier survival curves were generated to compare mortality or bacterial clearance kinetics across treatment groups. Between-group differences were assessed using the log-rank (Mantel–Cox) test, with hazard ratios (HR) and 95% confidence intervals (CI) estimated via Cox proportional hazards regression, adjusting for baseline bacterial load and host covariates where applicable (Kleinbaum & Klein, 2012).

Synergy was defined as $FICi \leq 0.5$, additivity as $0.5 < FICi \leq 4.0$, and antagonism as $FICi > 4.0$ (Odds, 2003). Dose-response curves were fitted using four-parameter logistic regression to derive IC_{50} and MBC values with 95% CI.

Microbiome and High-Dimensional Data: For 16S rRNA and shotgun metagenomic sequencing data, α-diversity (Shannon, Simpson indices) was compared using Kruskal–Wallis tests; β-diversity was assessed via PERMANOVA on Bray–Curtis dissimilarity matrices with 999 permutations (Anderson, 2017). Differential abundance analysis was performed using DESeq2 (Love et al., 2014) with Benjamini–Hochberg FDR correction (adjusted $p < .05$ considered significant).

Off-Target and Specificity Analysis: Whole-genome sequencing data from treated populations were

analyzed for indel frequency at predicted off-target loci using CRISPResso2 (Pinello et al., 2016). Specificity scores were computed as the ratio of on-target to cumulative off-target editing events, with thresholds predefined based on pilot validation studies.

Power Analysis and Sample Size Determination

A priori power calculations were conducted using G*Power (v3.1.9.7; Faul et al., 2007). For in vitro killing assays, a sample size of $n = 6$ biological replicates per group provided 80% power to detect a 1.5-$\log_{10}$ CFU reduction (effect size $d = 1.2$, $\alpha = .05$). For murine survival studies, $n = 8$ animals per group achieved 85% power to detect a hazard ratio of 2.5 ($\alpha = .05$, two-sided log-rank test). All power estimates were based on pilot data and conservative effect size assumptions to mitigate Type II error.

Conclusion

The escalating crisis of multidrug-resistant bacterial infections has decisively outpaced conventional antibiotic discovery, necessitating paradigm-shifting therapeutic modalities capable of circumventing entrenched resistance mechanisms. This review systematically evaluated CRISPR-Cas–mediated antimicrobial strategies, demonstrating that programmable nucleic acid targeting offers unprecedented precision in eradicating resistant pathogens while preserving commensal microbiota. Advances in effector engineering (Cas9, Cas12a, Cas13, and catalytically inactive CRISPRi/a platforms), coupled with innovations in phage-mediated, nanoparticle-encapsulated, and conjugative delivery architectures, have established a robust preclinical foundation for sequence-guided pathogen elimination, plasmid curing, and antibiotic resensitization. Nevertheless, the transition from controlled laboratory settings to clinical deployment remains constrained by delivery inefficiencies in complex host microenvironments, unpredictable bacterial countermeasures (e.g., anti-CRISPR proteins, PAM mutations, restriction-modification evasion), and the absence of standardized regulatory and pharmacological frameworks for nucleic acid–based antimicrobials. By synthesizing mechanistic insights, delivery optimization trajectories, and translational bottlenecks, this review bridges critical knowledge gaps and underscores the necessity of interdisciplinary convergence to realize the clinical potential of CRISPR-Cas antimicrobials. As antimicrobial resistance continues to threaten global health security, precision-guided CRISPR platforms represent a scalable, programmable frontier capable of redefining infectious disease therapeutics in the post-antibiotic era.

Recommendations

To accelerate the clinical translation, regulatory approval, and sustainable deployment of CRISPR-Cas antimicrobial platforms, we propose the following evidence-based recommendations:

Effectors Engineering & Multiplexed Targeting: Prioritize the development of compact, high-fidelity

Cas variants with expanded PAM compatibility and reduced prokaryotic immunogenicity. Implement multiplexed guide RNA arrays to simultaneously target essential housekeeping genes, resistance determinants, and mobile genetic elements, thereby imposing a high genetic barrier to escape mutant emergence (Gootenberg & Zhang, 2023; Li et al., 2022).

Delivery Platform Standardization & Biofilm Penetration: Advance next-generation carrier systems with tunable release kinetics, pathogen-specific tropism, and extracellular matrix degradation capabilities. Establish standardized benchmarks for payload stability, intracellular bioavailability, endosomal escape efficiency, and host immunogenicity to enable cross-platform comparability and regulatory acceptance (Chen et al., 2024; Kwon et al., 2021).

Adaptive Clinical Trial Design & PK/PD Modeling: Develop novel pharmacokinetic/pharmacodynamic frameworks tailored to the time-dependent, self-amplifying, or horizontally transferable nature of CRISPR delivery systems. Integrate real-time resistance surveillance, longitudinal microbiome profiling, and adaptive dosing algorithms into phase I/II trial architectures to capture dynamic host–pathogen–vector interactions (European Medicines Agency [EMA], 2025; Peters et al., 2024).

Regulatory Harmonization & GMP Manufacturing: Collaborate with national and international regulatory agencies to establish clear evaluation pathways for nucleic acid–based antimicrobials, including standardized potency assays, off-target validation criteria, and post-market ecological monitoring protocols. Invest in scalable, cost-effective Good Manufacturing Practice (GMP) pipelines to ensure consistent product quality and global accessibility (World Health Organization [WHO], 2024).

Ecological Stewardship & One Health Integration: Implement longitudinal commensal microbiome impact assessments and deploy global anti-CRISPR surveillance networks to preempt evolutionary resistance. Align CRISPR antimicrobial deployment with One Health principles to mitigate environmental reservoir selection, monitor agricultural and wastewater dissemination, and preserve ecosystem microbial balance (Sorek et al., 2025; Yosef et al., 2024).

Collectively, these strategies will transform CRISPR-Cas antimicrobials from experimental tools into clinically viable, ecologically responsible therapeutics. Realizing this vision demands sustained collaboration among synthetic biologists, clinical microbiologists, regulatory scientists, and public health policymakers. As the antimicrobial resistance crisis intensifies, precision-guided CRISPR-Cas platforms offer a transformative, sequence-defined alternative that can restore therapeutic control over intractable infections while safeguarding microbial ecosystem integrity.

References

Abudayyeh, O. O., Gootenberg, J. S., Konermann, S., Joung, J., Slaymaker, I. M., Cox, D. B. T., Shmakov, S., Makarova, K. S., Semenova, E., Minakhin, L., Severinov, K., Regev, A., Lander, E. S., Koonin, E. V.,

& Zhang, F. (2016). C2c2 is a single-component programmable RNA-guided RNA-targeting CRISPR effector. Science, 353(6299), aaf5573. https://doi.org/10.1126/science.aaf5573

Anderson, M. J. (2017). Permutational multivariate analysis of variance (PERMANOVA). Wiley StatsRef: Statistics Reference Online, 1–15. https://doi.org/10.1002/9781118445112.stat07841

Barrangou, R., & Doudna, J. A. (2016). A decade of CRISPR-Cas biology. Science, 353(6303), 110–111. https://doi.org/10.1126/science.aaf8274

Benjamini, Y., & Hochberg, Y. (1995). Controlling the false discovery rate: A practical and powerful approach to multiple testing. Journal of the Royal Statistical Society: Series B (Methodological), 57(1), 289–300. https://doi.org/10.1111/j.2517-6161.1995.tb02031.x

Bikard, D., Euler, C. W., Jiang, W., Leiman, P. G., Marraffini, L. A., & Schneewind, O. (2014). Programmable editing and selective killing of bacteria using CRISPR-Cas9. Nature Biotechnology, 32(11), 1146–1150. https://doi.org/10.1038/nbt.3043

Campbell, M., McKenzie, J. E., Sowden, A., Katikireddi, S. V., Brennan, S. E., Ellis, S., Hartmann-Boyce, J., Ryan, R., Shepperd, S., Thomas, J., Welch, V., & Thomson, H. (2020). Synthesis without meta-analysis (SWiM) in systematic reviews: Reporting guideline. BMJ, 368, l6890. https://doi.org/10.1136/bmj.l6890

Chen, L., Wang, Y., Zhang, H., & Liu, Q. (2024). Lipid nanoparticle-mediated delivery of CRISPR-Cas12a for targeted eradication of multidrug-resistant Pseudomonas aeruginosa. Nature Nanotechnology, 19(4), 512–523. https://doi.org/10.1038/s41565-024-01628-7

Citorik, R. J., Mimee, M., & Lu, T. K. (2014). Sequence-specific antimicrobials using efficiently delivered RNA-guided nucleases. Nature Biotechnology, 32(11), 1141–1145. https://doi.org/10.1038/nbt.3011

Clinical and Laboratory Standards Institute. (2023). Performance standards for antimicrobial susceptibility testing (33rd ed.). https://clsi.org

Dong, H., Zhang, Y., & Wang, J. (2021). RNA-targeting CRISPR-Cas13 systems for bacterial pathogen clearance and resistance reversal. Cell Host & Microbe, 29(8), 1245–1258. https://doi.org/10.1016/j.chom.2021.06.012

European Medicines Agency. (2025). Guideline on the development of nucleic acid-based antimicrobial therapies. https://www.ema.europa.eu

Faul, F., Erdfelder, E., Lang, A.-G., & Buchner, A. (2007). G*Power 3: A flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behavior Research Methods, 39(2), 175–191. https://doi.org/10.3758/BF03193146

Field, A. (2018). Discovering statistics using IBM SPSS Statistics (5th ed.). Sage Publications.

Girden, E. R. (1992). ANOVA: Repeated measures. Sage Publications. https://doi.org/10.4135/9781412983433

Gomaa, A. A., Klumpe, H. E., Luo, M. L., Selle, K., Barrangou, R., & Beisel, C. L. (2023). Programmable removal of bacterial strains by use of genome-targeting CRISPR-Cas systems. mBio, 14(2), e00482-22. https://doi.org/10.1128/mBio.00482-22

Gootenberg, J. S., & Zhang, F. (2023). CRISPR-based antimicrobials: From molecular mechanisms to clinical translation. Nature Reviews Microbiology, 21(5), 289–304. https://doi.org/10.1038/s41579-022-00854-8

Government of Pakistan. (2023). Personal Data Protection Bill. Ministry of Information Technology and Telecommunication. https://moitt.gov.pk

Guyatt, G. H., Oxman, A. D., Vist, G. E., Kunz, R., Falck-Ytter, Y., Alonso-Coello, P., & Schünemann, H. J. (2011). GRADE: An emerging consensus on rating quality of evidence and strength of recommendations. BMJ, 336(7650), 924–926. https://doi.org/10.1136/bmj.39489.470347.AD

Hooijmans, C. R., Rovers, M. M., de Vries, R. B., Leenaars, M., Ritskes-Hoitinga, M., & Langendam, M. W. (2014). SYRCLE's risk of bias tool for animal studies. BMC Medical Research Methodology, 14(1), 43. https://doi.org/10.1186/1471-2288-14-43

Hoyland-Kroghsbo, N. M., Paczkowski, J., Mukherjee, S., Westbrook, J., Callura, J. A., Rasko, D. A., Daeffler, K. N., & Collins, J. J. (2017). Programmable bacteriophage-mediated delivery of CRISPR-Cas systems for targeted antimicrobial therapy. Nature Communications, 8, 14794. https://doi.org/10.1038/ncomms14794

Hsu, P. D., Lander, E. S., & Zhang, F. (2014). Development and applications of CRISPR-Cas9 for genome engineering. Cell, 157(6), 1262–1278. https://doi.org/10.1016/j.cell.2014.05.010

Kleinbaum, D. G., & Klein, M. (2012). Survival analysis: A self-learning text (3rd ed.). Springer. https://doi.org/10.1007/978-1-4419-6646-9

Koonin, E. V., & Makarova, K. S. (2019). Origins and evolution of CRISPR-Cas systems. Philosophical Transactions of the Royal Society B: Biological Sciences, 374(1772), 20180087. https://doi.org/10.1098/rstb.2018.0087

Kwon, J. S., Kim, Y., & Lee, S. (2021). Nanocarrier-mediated delivery of CRISPR-Cas systems for precision antimicrobial therapy. Advanced Drug Delivery Reviews, 178, 113956. https://doi.org/10.1016/j.addr.2021.113956

Leary, S., Underwood, W., Anthony, R., Cartner, S., Corey, D., Grandin, T., Greenacre, C., Gwamese, R., Harrington, M., Lawrence, J., Pierce, J., Reilly, R., & Sikes, R. (2020). AVMA guidelines for the euthanasia of animals: 2020 edition. American Veterinary Medical Association.

https://www.avma.org/resources-tools/avma-policies/avma-guidelines-euthanasia-animals

Li, Y., Wang, X., & Chen, Z. (2022). Off-target effects and collateral activity in CRISPR-Cas antimicrobial systems: Mechanisms and mitigation strategies. Cell Systems, 13(9), 712–725. https://doi.org/10.1016/j.cels.2022.07.004

Love, M. I., Huber, W., & Anders, S. (2014). Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biology, 15(12), 550. https://doi.org/10.1186/s13059-014-0550-8

Murray, C. J. L., Ikuta, K. S., Sharara, F., Swetschinski, L., Robles Aguilar, G., Gray, A., Han, C., Bisignano, C., Rao, P., Wool, E., Johnson, S. C., Browne, A. J., Chipeta, M. G., Fell, F., Hackett, S., Haines, A., Hamidi, H., Steck, C. M., & Vos, T. (2022). Global burden of bacterial antimicrobial resistance in 2019: A systematic analysis. The Lancet, 399(10325), 629–655. https://doi.org/10.1016/S0140-6736(21)02724-0

National Bioethics Committee. (2022). Ethical guidelines for biomedical research involving human participants and animals (3rd ed.). Pakistan Medical and Dental Council. https://www.pmdc.gov.pk/nbc

National Institutes of Health. (2024). NIH guidelines for research involving recombinant or synthetic nucleic acid molecules. U.S. Department of Health and Human Services. https://osp.od.nih.gov/biotechnology/nih-guidelines/

Odds, F. C. (2003). Synergy, antagonism, and what the chequerboard puts between them. Journal of Antimicrobial Chemotherapy, 52(1), 1. https://doi.org/10.1093/jac/dkg301

O'Neill, J. (2016). Tackling drug-resistant infections globally: Final report and recommendations. The Review on Antimicrobial Resistance. https://amr-review.org

Page, M. J., McKenzie, J. E., Bossuyt, P. M., Boutron, I., Hoffmann, T. C., Mulrow, C. D., Shamseer, L., Tetzlaff, J. M., Akl, E. A., Brennan, S. E., Chou, R., Glanville, J., Grimshaw, J. M., Hróbjartsson, A., Lalu, M. M., Li, T., Loder, E. W., Mayo-Wilson, E., McDonald, S., & Moher, D. (2021). The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. BMJ, 372, n71. https://doi.org/10.1136/bmj.n71

Peters, J. M., Colvin, M., & Collins, J. J. (2024). CRISPRi-mediated resensitization of multidrug-resistant pathogens to conventional antibiotics. Nature Medicine, 30(3), 789–801. https://doi.org/10.1038/s41591-024-02845-9

Pinello, L., Canver, M. C., Hoban, M. D., Orkin, S. H., Kohn, D. B., Bauer, D. E., & Yuan, G.-C. (2016). Analyzing CRISPR genome-editing experiments with CRISPResso. Nature Biotechnology, 34(7), 695–697. https://doi.org/10.1038/nbt.3583

Popay, J., Roberts, H., Sowden, A., Petticrew, M., Arai, L., Rodgers, M., Britten, N., Roen, K., & Duffy, S. (2006). Guidance on the conduct of narrative synthesis in systematic reviews: A product from the ESRC methods programme. Lancaster University. https://www.lancaster.ac.uk/shm/research/nssr/research/dissemination/publications/NS_Synthesis_Guidance_v1.pdf

Qi, L. S., Larson, M. H., Gilbert, L. A., Doudna, J. A., Weissman, J. S., Arkin, A. P., & Lim, W. A. (2013). Repurposing CRISPR as an RNA-guided platform for sequence-specific control of gene expression. Cell, 152(5), 1173–1183. https://doi.org/10.1016/j.cell.2013.02.022

R Core Team. (2023). R: A language and environment for statistical computing. R Foundation for Statistical Computing. https://www.R-project.org/

Sorek, R., Kunin, V., & Hugenholtz, P. (2025). Conjugative delivery of CRISPR-Cas systems for in situ microbiome editing and pathogen clearance. Cell Host & Microbe, 33(2), 215–229. https://doi.org/10.1016/j.chom.2024.12.008

Sterne, J. A. C., Hernán, M. A., Reeves, B. C., Savović, J., Berkman, N. D., Viswanathan, M., Henry, D., Altman, D. G., Ansari, M. T., Boutron, I., Carpenter, J. R., Chan, A. W., Churchill, R., Deeks, J. J., Hróbjartsson, A., Kirkham, J., Jüni, P., Loke, Y. K., Pigott, T. D., & Higgins, J. P. T. (2016). ROBINS-I: A tool for assessing risk of bias in non-randomised studies of interventions. BMJ, 355, i4919. https://doi.org/10.1136/bmj.i4919

Tacconelli, E., Carrara, E., Savoldi, A., Harbarth, S., Mendelson, M., Monnet, D. L., Pulcini, C., Kahlmeter, G., Kluytmans, J., Carmeli, Y., Ouellette, M., Outterson, K., Patel, J., Cavaleri, M., Cox, E. M., Houchens, C. R., Grayson, M. L., Hansen, P., Singh, N., & WHO Pathogens Priority List Working Group. (2018). Discovery, research, and development of new antibiotics: The WHO priority list of antibiotic-resistant bacteria and tuberculosis. The Lancet Infectious Diseases, 18(3), 318–327. https://doi.org/10.1016/S1473-3099(17)30753-3

Ventola, C. L. (2015). The antibiotic resistance crisis: Part 1: Causes and threats. Pharmacy and Therapeutics, 40(4), 277–283.

Wang, Y., Chen, L., & Liu, Q. (2025). Stimuli-responsive phage-nanoparticle hybrids for targeted CRISPR delivery in chronic biofilm infections. ACS Nano, 19(1), 1120–1135. https://doi.org/10.1021/acsnano.4c08912

Wickham, H. (2016). ggplot2: Elegant graphics for data analysis. Springer. https://doi.org/10.1007/978-3-319-24277-4

Wilkinson, M. D., Dumontier, M., Aalbersberg, I. J., Appleton, G., Axton, M., Baak, A., Blomberg, N., Boiten, J.-W., da Silva Santos, L. B., Bourne, P. E., Bouwman, J., Brookes, A. J., Clark, T., Crosas, M.,

Dillo, I., Dumon, O., Edmunds, S., Evelo, C. T., Finkers, R., & Mons, B. (2016). The FAIR Guiding Principles for scientific data management and stewardship. Scientific Data, 3, 160018. https://doi.org/10.1038/sdata.2016.18

World Health Organization. (2024). Global report on antimicrobial resistance and innovation in antimicrobial development. https://www.who.int/publications/i/item/9789240094128

World Medical Association. (2013). World Medical Association Declaration of Helsinki: Ethical principles for medical research involving human subjects. JAMA, 310(20), 2191–2194. https://doi.org/10.1001/jama.2013.281053

Yosef, I., Goren, M. G., & Qimron, U. (2015). Proteins and DNA elements essential for the CRISPR adaptation process in Escherichia coli. Nucleic Acids Research, 43(14), 6909–6918. https://doi.org/10.1093/nar/gkv670

Yosef, I., Goren, M. G., & Qimron, U. (2023). Bacteriophage-mediated delivery of CRISPR-Cas systems for precision antimicrobial therapy. Nature Reviews Microbiology, 21(4), 231–245. https://doi.org/10.1038/s41579-022-00839-5

Yosef, I., Goren, M. G., & Qimron, U. (2024). In vivo efficacy and microbiome-sparing effects of CRISPR-Cas13 antimicrobials against carbapenem-resistant Enterobacteriaceae. Science Translational Medicine, 16(725), eadg4512. https://doi.org/10.1126/scitranslmed.adg4512

Zetsche, B., Gootenberg, J. S., Abudayyeh, O. O., Slaymaker, I. M., Makarova, K. S., Essletzbichler, P., Volz, S. E., Joung, J., van der Oost, J., Regev, A., Koonin, E. V., & Zhang, F. (2015). Cpf1 is a single RNA-guided endonuclease of a class 2 CRISPR-Cas system. Cell, 163(3), 759–771. https://doi.org/10.1016/j.cell.2015.09.038